Pulished : October, 2018
ID: 118
Region: Global
Share on

The Cancer Immunotherapy Market Is Predicted To Reach USD 140.53 Billion By 2023 With A CAGR Of 12.40 % According To Market Data Forecast Report

Pulished: October, 2018
ID: 118
Share on

The Cancer Immunotherapy Market report published by Market Data Forecast provides a detailed account of the Market Trends via Customized Research presented as Strategic Analyses, Company Profiles, Competitive Landscape, etc. According to the report the Cancer Immunotherapy Market is estimated to be USD 78.33 Billion in 2018 and predicted to rise to USD 140.53 Billion by the end of 2023 with a CAGR of 12.40 %. The Market is categorized based on the Application into Breast, Lung, Melanoma, Colorectal, Head & Neck, Prostate and others. Based on product type, the market is categorized into Monoclonal Antibodies, Checkpoint inhibitors/immune modulators, Therapeutic cancer vaccines, Oncolytic virus immunotherapy, Cytokines, Adoptive T cell transfer, Adjuvant Immunotherapy, BCG and others. Based on Mode of administration, the market is categorized into Intravenous, Oral, Topical, and Intravesical. Based on end users, the market is categorized into hospitals, clinics. Further the market is also geographically segmented into North America, Europe, Asia-Pacific, Latin America and Middle-East & Africa.

The key factor that are driving the growth of the market are increasing occurrence of cancer, Changing life style, Smoking and excessive alcoholic intake, high efficacy of immunotherapy compared to other treatments, less side effects associated with cancer immunotherapy, reduced chance of recurrence of cancer. Various cancers like Melanoma shows resistance towards chemotherapy and radiation therapies, Cost of cancer therapies, limited information on cancer immunobiology are the major factors limiting the growth of the market.

In Application Segment, The lung cancer is predicted to witness the highest growth during the forecast period owing to increasing prevalence of this type of cancer all over the world. Based on Product type, Monoclonal antibodies segment is predicted to account the largest share of the global market due to effective results of cancer immunotherapy with monoclonal antibodies. Based on End users, Hospitals segment is predicted to have highest share in the market over the forecast period owing to increasing number of patients treated in hospitals.

North American region is predicted to account the highest share in the market which is mainly driven by the increasing incidence of cancer and increasing patient pool in U.S. Asia-Pacific region is expected to account the high CAGR during the forecast period due to increasing health care expenditure.

Major players that are influencing Global cancer immunotherapy Market are F. Hoffmann-La Roche Ltd, Amgen, Viralytics, Novartis Pharmaceuticals Corporation, Pfizer, GlaxoSmithKline Pharmaceuticals Limited, AstraZeneca plc, Medivation, Advaxis, Bristol-Myers Squibb, Merck & Co. and Celgene Corp, Immunomedics..

Browse through the full report at “http://www.marketdataforecast.com/market-reports/global-cancer-immunotherapy-market-1412/” and checkout our recent reports in the Therapeutics category at “http://www.marketdataforecast.com/research-reports/healthcare/therapeutics-11/”. For more insights and up-to-date industry news don’t forget subscribing to our newsletters.